Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | GRM5 | P41594 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656561 | 0.83 | MAPK1 (0.77) | MAPTSMN1; SMN2NPC1MAPK1HTT | |
| SCHEMBL2778972 | 0.83 | MAPK1 (0.60) | GCKMAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL2664782 | 0.81 | GCK (0.63) | GCKMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2664786 | 0.80 | GCK (0.61) | GCKMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2664747 | 0.78 | RAB9A (0.77) | GCKMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL24101767 | 0.77 | RAB9A (0.61) | GCKMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2664773 | 0.77 | ALDH1A1 (0.59) | MAPTRAB9ASMN1; SMN2NPC1HPGD | |
| SCHEMBL17379134 | 0.75 | GRM5 (0.71) | GRM5 | |
| SCHEMBL2664778 | 0.74 | GCK (0.63) | GCKRAB9ASMN1; SMN2NPC1HPGD | |
| SCHEMBL13292271 | 0.74 | GRM5 (0.56) | GCKMAPTRAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | GCK 2/4885MAPT 4022/4885RAB9A 3175/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | GCK 2/4885MAPT 4022/4885RAB9A 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.